Cipla USA Inc., a unit of Cipla Limited (500087), on Thursday said it has received approval from the U.S. Food and Drug Administration for its Albuterol Sulfate Inhalation Aerosol, a generic version of Ventolin HFA marketed by GlaxoSmithKline.
The product is the first AB-rated therapeutic equivalent of Ventolin HFA and is used to treat or prevent bronchospasm in adults and children aged four years and older, including exercise-induced bronchospasm.
According to IQVIA, the total U.S. albuterol market is valued at about $1.5 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.